JHOP Articles

Skip to main content

Practical Issues in Pharmacy Management

Comparing Granulocyte Colony-Stimulating Factors Prescribing Practices versus Guideline Recommendations in a Large Community Cancer Center

Kirollos S. Hanna, PharmD, BCPS, BCOP, Robert Mancini, PharmD, BCOP, FHOPA, Dave Wilson, PharmD, Dan Zuckerman, MD

Kirollos S. Hanna, PharmD, BCPS, BCOP; Robert Mancini, PharmD, BCOP; Dave Wilson, PharmD; Dan Zuckerman, MD

Multiple Myeloma

Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma

Meeting Highlights

ASCO Highlights

FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs

Immunotherapy

CAR T-Cell Therapy Targeting Solid Tumors

FDA Updates

Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer

Yvette Florio Lane

FDA Updates

First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL

Yvette Florio Lane

FDA Updates

Welcome to the Fourth Annual Oncology Guide to New FDA Approvals

FDA Updates

New Indications Approved by the FDA in 2018 for Oncology Drugs

Dalia Buffery, MA, ABD

FDA Updates

FDA Approvals of Novel Brand-Name Prescription Cancer Drugs in 2018

FDA Updates, Melanoma

Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

Page 151 of 199
Results 1501 - 1510 of 1986